EGFR and familial pancreatic carcinoma: The EGFR-tyrosine kinase inhibitor (EGFR-TKI) erlotinib is the only targeted agent to have demonstrated a small but significant improved survival in advanced pancreatic cancer when combined with gemcitabine [20].